Company Overview and News
KUALA LUMPUR (Oct 2): CIMB Bank Bhd has teamed up with payment system company GHL Systems Bhd to become the first bank in Malaysia to introduce quick response (QR) payment acceptance at its terminals, accepting payments through six major mobile wallets on one terminal.
KUALA LUMPUR (July 18): AllianceDBS Research said GHL Systems Bhd (Ghlsys) had on July 17 tested previous day’s high of RM1.64 before closing at RM1.63 (up 1 sen or 0.61%).
KUALA LUMPUR (July 16): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (July 17) may include the following: DBE Gurney Resources Bhd, KLCC Stapled Group, Salcon Bhd, TFP Solutions Bhd, Pasdec Holdings Bhd, GHL Systems Bhd, Nova MSC Bhd and Xinghe Holdings Bhd.
6912 0145 0026 BSMAF 0095 0021 1818
KUALA LUMPUR (July 16): GHL Systems Bhd has been appointed as a direct merchant acquirer for UnionPay International in Malaysia.
Nova MSC Bhd (July 10, 18 sen) Not rated: Nova MSC Bhd is an ACE Market-listed company primarily involved in developing and supplying smart e-solutions in three main segments: smart healthcare, government digitalisation, and building automation and control. It targets both government and private entities. All its softwares are developed fully in-house. Nova’s current operations are mainly in Singapore (98% of its financial year 2018 [FY18] revenue) but it also has presence in other Southeast Asian countries such as Brunei, Malaysia, and Indonesia.
5216 4456 0026 0021
GHL Systems Bhd (-ve) Shares in payment service provider GHL Systems Bhd (fundamental: 2.2/3, valuation: 0.2/3), which triggered our momentum algorithm last Friday for the first time this year, closed five sen or 3.15% higher at RM1.64.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...